| Dr Kelly Jacqueline Kays Foltermann, MD | |
|
1224 Trotwood Ave, Columbia, TN 38401-4802 | |
| (931) 380-4072 | |
| (931) 490-7043 |
| Full Name | Dr Kelly Jacqueline Kays Foltermann |
|---|---|
| Gender | Female |
| Speciality | Internal Medicine |
| Experience | 13 Years |
| Location | 1224 Trotwood Ave, Columbia, Tennessee |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1407141773 | NPI | - | NPPES |
| 3710089 | Medicaid | TN |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208000000X | Pediatrics | 52773 (Tennessee) | Secondary |
| 207R00000X | Internal Medicine | 52773 (Tennessee) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Maury Regional Hospital | Columbia, TN | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Maury Regional Medical Group, Inc | 7911810742 | 97 |
News Archive
The human leucocyte antigen-C and killer immunoglobin-like receptor genotypes are associated with response to interferon-based therapy in patients with chronic hepatitis B virus infection positive for hepatitis B e antigen, say researchers.
Rexahn Pharmaceuticals, Inc. a clinical stage biopharmaceutical company developing best-in-class therapeutics for the treatment of cancer, is providing an overview of its three clinical development programs and Year for the year ended December 31, 2013.
University of Liverpool researchers, working with F2G Limited (Eccles, Manchester), have developed a new antifungal drug to help in the treatment of life threatening invasive fungal infections such as invasive aspergillosis.
Immunomedics, Inc., a biopharmaceutical company primarily focused on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases, today reported financial results for the second quarter ended December 31, 2010.
› Verified 8 days ago
| Entity Name | Maury Regional Medical Group, Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1205886264 PECOS PAC ID: 7911810742 Enrollment ID: O20040227000252 |
News Archive
The human leucocyte antigen-C and killer immunoglobin-like receptor genotypes are associated with response to interferon-based therapy in patients with chronic hepatitis B virus infection positive for hepatitis B e antigen, say researchers.
Rexahn Pharmaceuticals, Inc. a clinical stage biopharmaceutical company developing best-in-class therapeutics for the treatment of cancer, is providing an overview of its three clinical development programs and Year for the year ended December 31, 2013.
University of Liverpool researchers, working with F2G Limited (Eccles, Manchester), have developed a new antifungal drug to help in the treatment of life threatening invasive fungal infections such as invasive aspergillosis.
Immunomedics, Inc., a biopharmaceutical company primarily focused on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases, today reported financial results for the second quarter ended December 31, 2010.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Kelly Jacqueline Kays Foltermann, MD 854 W James Campbell Blvd, Suite 303, Columbia, TN 38401-4659 Ph: (931) 380-4072 | Dr Kelly Jacqueline Kays Foltermann, MD 1224 Trotwood Ave, Columbia, TN 38401-4802 Ph: (931) 380-4072 |
News Archive
The human leucocyte antigen-C and killer immunoglobin-like receptor genotypes are associated with response to interferon-based therapy in patients with chronic hepatitis B virus infection positive for hepatitis B e antigen, say researchers.
Rexahn Pharmaceuticals, Inc. a clinical stage biopharmaceutical company developing best-in-class therapeutics for the treatment of cancer, is providing an overview of its three clinical development programs and Year for the year ended December 31, 2013.
University of Liverpool researchers, working with F2G Limited (Eccles, Manchester), have developed a new antifungal drug to help in the treatment of life threatening invasive fungal infections such as invasive aspergillosis.
Immunomedics, Inc., a biopharmaceutical company primarily focused on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases, today reported financial results for the second quarter ended December 31, 2010.
› Verified 8 days ago
Jessica Joseph-alexis, DO Internal Medicine Medicare: Medicare Enrolled Practice Location: 1220 Trotwood Ave Ste 401, Columbia, TN 38401 Phone: 931-388-8622 | |
Dr. Hany Nimr Rezk, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 854 W James Campbell Blvd, Ste. 101a, Columbia, TN 38401 Phone: 931-388-3209 Fax: 931-388-0105 | |
Anthony Donald Haase Iii, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 1224 Trotwood Ave, Columbia, TN 38401 Phone: 931-380-4072 Fax: 931-490-7043 | |
Christopher R Edwards, MD Internal Medicine Medicare: Medicare Enrolled Practice Location: 1224 Trotwood Ave, Columbia, TN 38401 Phone: 931-381-1111 | |
Dr. Cheryl Buttram Clayton, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 854 W James Campbell Blvd, Ste. 101a, Columbia, TN 38401 Phone: 931-388-3209 Fax: 931-388-0105 | |
John Spencer Jensen, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 1222 Trotwood Ave, Suite 503, Columbia, TN 38401 Phone: 931-490-7775 Fax: 931-490-7797 | |
Dominic J Papa, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 1224 Trotwood Ave, Columbia, TN 38401 Phone: 931-380-4032 Fax: 931-490-7043 |